Davidson & Garrard Inc. trimmed its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 4.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,394 shares of the medical research company’s stock after selling 2,653 shares during the period. Thermo Fisher Scientific makes up approximately 2.4% of Davidson & Garrard Inc.’s portfolio, making the stock its 2nd biggest holding. Davidson & Garrard Inc.’s holdings in Thermo Fisher Scientific were worth $10,102,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of TMO. Proficio Capital Partners LLC lifted its stake in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after acquiring an additional 253 shares during the period. Chicago Partners Investment Group LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at $108,000. Shine Investment Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the second quarter valued at $113,000. Ropes Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 97 shares during the period. Finally, Atlantic Trust LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at $138,000. Institutional investors and hedge funds own 86.16% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE TMO) traded up $0.42 during mid-day trading on Wednesday, hitting $182.45. The stock had a trading volume of 2,229,200 shares, compared to its average volume of 1,558,350. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $72,570.00, a price-to-earnings ratio of 20.00, a PEG ratio of 1.67 and a beta of 1.06. Thermo Fisher Scientific Inc has a fifty-two week low of $139.88 and a fifty-two week high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period last year, the company earned $2.03 earnings per share. equities analysts expect that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be issued a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.33%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is currently 10.19%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the sale, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.49% of the stock is currently owned by company insiders.

Several brokerages have commented on TMO. Leerink Swann reissued an “outperform” rating and set a $200.00 price objective (down previously from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective for the company in a report on Tuesday, October 31st. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. Jefferies Group restated a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Finally, Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target for the company. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $205.21.

ILLEGAL ACTIVITY NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/06/davidson-garrard-inc-has-10-10-million-position-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.